{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T08:06:48Z","timestamp":1786867608177,"version":"build-2736575974"},"reference-count":38,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,8,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We analyzed outcomes after hematopoietic cell transplantation (HCT) in 257 patients, 3 to 72.7 years old (median, 43 y), with secondary myelodysplastic syndrome (MDS) including those with transformation to acute myeloid leukemia (tAML). Conditioning regimens included high-dose total-body irradiation (TBI)\/chemotherapy (n = 83); busulfan (BU)\/cyclophosphamide (CY) (BUCY, n = 122; with BU targeting [tBUCY], n = 93); fludarabine (Flu) with tBU (FLUtBU; n = 12); Flu plus 200 cGy TBI (n = 26); and miscellaneous regimens (n = 14). Donors were HLA-identical or partially mismatched family members in 135 and unrelated individuals in 122 patients. Five-year relapse-free survival was highest (43%) and nonrelapse mortality lowest (28%) among tBUCY-conditioned patients. Outcomes were compared with results in 339 patients who received transplants for de novo MDS\/tAML, and a multivariate analysis failed to show significant differences in outcome between the 2 cohorts. Relapse probability and relapse-free survival correlated significantly with disease stage (P &lt; .001) and karyotype (P &lt; .001). Relapse incidence was lower (P = .003) and relapse-free survival superior (P = .02) with unrelated donor transplants. The data suggest that overall inferior outcome in patients with secondary MDS\/tAML was related to the frequency of high-risk cytogenetics. For both cohorts, transplantation outcomes improved over the time interval studied.<\/jats:p>","DOI":"10.1182\/blood-2007-02-076307","type":"journal-article","created":{"date-parts":[[2007,5,9]],"date-time":"2007-05-09T02:43:16Z","timestamp":1178678596000},"page":"1379-1387","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":139,"title":["Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders"],"prefix":"10.1182","volume":"110","author":[{"given":"ChunKang","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Hematology, Shanghai Sixth People's Hospital, Shanghai JiaoTong University, Shanghai, People's Republic of China;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry E.","family":"Storer","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Scott","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen M.","family":"Bryant","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Shulman","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E.","family":"Flowers","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Witherspoon","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Nash","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean E.","family":"Sanders","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Bedalov","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Clurman","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Storb","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick R.","family":"Appelbaum","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111711472611200_B1","first-page":"543","article-title":"Prognosis and therapy of secondary myelodysplastic syndromes [review].","volume":"83","author":"Estey","year":"1998","journal-title":"Haematologica"},{"key":"2019111711472611200_B2","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/cncr.21699","article-title":"Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"2019111711472611200_B3","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.V88.7.2473.bloodjournal8872473","article-title":"Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.","volume":"88","author":"Beran","year":"1996","journal-title":"Blood"},{"key":"2019111711472611200_B4","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood.V89.7.2578","article-title":"Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy.","volume":"89","author":"Anderson","year":"1997","journal-title":"Blood"},{"key":"2019111711472611200_B5","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/sj.bmt.1700971","article-title":"Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia.","volume":"20","author":"Ballen","year":"1997","journal-title":"Bone Marrow Transplant"},{"key":"2019111711472611200_B6","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms [review].","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"2019111711472611200_B7","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1200\/JCO.2001.19.8.2134","article-title":"Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia.","volume":"19","author":"Witherspoon","year":"2001","journal-title":"J Clin Oncol"},{"key":"2019111711472611200_B8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.bbmt.2006.10.030","article-title":"Marrow fibrosis as a risk factor for post-transplant outcome in patients with advanced MDS or AML with multilineage dysplasia.","volume":"13","author":"Scott","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111711472611200_B9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes.","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"key":"2019111711472611200_B10","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V57.2.267.bloodjournal572267","article-title":"Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.","volume":"57","author":"Sullivan","year":"1981","journal-title":"Blood"},{"key":"2019111711472611200_B11","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood. 1998;91:1100].","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"2019111711472611200_B12","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/0360-3016(82)90083-9","article-title":"Marrow transplantation for acute nonlymphoblastic leukemia in first remission using fractionated or single-dose irradiation.","volume":"8","author":"Thomas","year":"1982","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2019111711472611200_B13","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1200\/JCO.1996.14.1.220","article-title":"Allogeneic marrow transplantation for myelodysplastic syndrome with advanced disease morphology: a phase II study of busulfan, cyclophosphamide, and total-body irradiation and analysis of prognostic factors.","volume":"14","author":"Anderson","year":"1996","journal-title":"J Clin Oncol"},{"key":"2019111711472611200_B14","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1182\/blood.V89.8.3055","article-title":"Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.","volume":"89","author":"Slattery","year":"1997","journal-title":"Blood"},{"key":"2019111711472611200_B15","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2002-11-3567","article-title":"Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.","volume":"102","author":"Bornh\u00e4user","year":"2003","journal-title":"Blood"},{"issue":"pt 1","key":"2019111711472611200_B16","first-page":"208a","article-title":"Relationship between conditioning intensity and comorbidity in patients (pts) with acute myeloid leukemia (AML) or myelodysplasia (MDS) receiving allogeneic hematopoietic cell transplantation [abstract].","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"2019111711472611200_B17","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.bbmt.2004.12.326","article-title":"HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia.","volume":"11","author":"Baron","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111711472611200_B18","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJM198603203141201","article-title":"Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.","volume":"314","author":"Storb","year":"1986","journal-title":"N Engl J Med"},{"key":"2019111711472611200_B19","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood.V65.6.1325.bloodjournal6561325","article-title":"Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia.","volume":"65","author":"Deeg","year":"1985","journal-title":"Blood"},{"key":"2019111711472611200_B20","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood-2002-08-2628","article-title":"Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation.","volume":"102","author":"Mielcarek","year":"2003","journal-title":"Blood"},{"key":"2019111711472611200_B21","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1182\/blood.V85.12.3746.bloodjournal85123746","article-title":"Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study.","volume":"85","author":"Nash","year":"1995","journal-title":"Blood"},{"key":"2019111711472611200_B22","first-page":"681","article-title":"Acute graft-versus-host disease.","volume-title":"Clinical Bone Marrow and Blood Stem Cell Transplantation","author":"Deeg","year":"2000"},{"key":"2019111711472611200_B23","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2019111711472611200_B24","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"2019111711472611200_B25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables (with discussion).","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc [Ser B]"},{"key":"2019111711472611200_B26","first-page":"131","article-title":"World Health Organization classification of the acute leukemias and myelodysplastic syndrome.","volume":"72","author":"Bennett","year":"2000","journal-title":"Int J Hematol"},{"key":"2019111711472611200_B27","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1200\/JCO.2003.07.113","article-title":"Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients [review].","volume":"21","author":"Armitage","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019111711472611200_B28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s004320050156","article-title":"Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies [review].","volume":"124","author":"Kollmannsberger","year":"1998","journal-title":"J Cancer Res Clin Oncol"},{"key":"2019111711472611200_B29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series.","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"key":"2019111711472611200_B30","first-page":"1997","article-title":"Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia.","volume":"100","author":"Sierra","year":"2002","journal-title":"Blood"},{"key":"2019111711472611200_B31","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2000.18.5.963","article-title":"Allogeneic bone marrow transplantation for therapy-related myelodsyplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French Society of bone marrow transplantation.","volume":"18","author":"Yakoub-Agha","year":"2000","journal-title":"J Clin Oncol"},{"key":"2019111711472611200_B32","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood.V92.6.1910","article-title":"Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation.","volume":"92","author":"Nevill","year":"1998","journal-title":"Blood"},{"key":"2019111711472611200_B33","first-page":"S25","article-title":"Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score.","volume":"12","author":"Appelbaum","year":"1998","journal-title":"Leukemia"},{"key":"2019111711472611200_B34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.bbmt.2005.12.036","article-title":"Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan\/cyclophosphamide regimen.","volume":"12","author":"Deeg","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111711472611200_B35","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.bbmt.2005.12.034","article-title":"Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation.","volume":"12","author":"Bacigalupo","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"2019111711472611200_B36","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood-2003-06-2163","article-title":"Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies.","volume":"103","author":"Poppe","year":"2004","journal-title":"Blood"},{"key":"2019111711472611200_B37","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2002-09-2768","article-title":"Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hemopoietic stem cell transplantation.","volume":"102","author":"Wells","year":"2003","journal-title":"Blood"},{"key":"2019111711472611200_B38","first-page":"72","article-title":"New insights into the biology of acute myeloid leukemia and their impact on treatment.","volume":"87","author":"Hiddemann","year":"2003","journal-title":"Verh Dtsch Ges Path"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/4\/1379\/1480587\/zh801607001379.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/4\/1379\/1480587\/zh801607001379.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T03:12:33Z","timestamp":1736997153000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/4\/1379\/23208\/Hematopoietic-cell-transplantation-in-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,15]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,8,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-02-076307","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,15]]}}}